title: Reply.
authors.affiliation: London, United Kingdom.
authors.forename: Maria
authors.initials: M
authors.lastname: Eleftheriadou
authors.affiliation: London, United Kingdom.
authors.forename: Clara
authors.initials: C
authors.lastname: Vazquez-Alfageme
authors.affiliation: London, United Kingdom.
authors.forename: Cristina Maria
authors.initials: CM
authors.lastname: Citu
authors.affiliation: London, United Kingdom.
authors.forename: Roxanne
authors.initials: R
authors.lastname: Crosby-Nwaobi
authors.affiliation: London, United Kingdom.
authors.forename: Sobha
authors.initials: S
authors.lastname: Sivaprasad
authors.affiliation: London, United Kingdom.
authors.forename: Philip
authors.initials: P
authors.lastname: Hykin
authors.affiliation: London, United Kingdom.
authors.forename: Robin D
authors.initials: RD
authors.lastname: Hamilton
authors.affiliation: London, United Kingdom.
authors.forename: Praveen J
authors.initials: PJ
authors.lastname: Patel
mesh_terms: D006801:Humans; D008268:Macular Degeneration; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor